Melanoma Stage IV

Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Screening for Brain Metastases

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma

Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma